DIA Bayesian Scientific Working Group Update 2022
Explore the latest updates from the DIA Bayesian Scientific Working Group (BSWG) in the 2022 JSM F2F Meeting. Discover insights on Bayesian methods in COVID research, innovative clinical trials, and more presented by industry experts. Join the discussion on improving patient outcomes and decision-making in medical product development.
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author. If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
DIA Bayesian Scientific Working Group Update 2022 JSM F2F Meeting August 9th, 2022
Meeting Agenda Welcome, BSWG Overview: Freda Cooner (Arcutis) BSWG Sub-Team Updates Medical Outreach: Jennifer Clark (FDA) Safety: Melvin Munsaka (Abbvie) COVID19: Estelle Russek-Cohen (Independent Consultant) IDSWG Update: Sammi Tang (Sevier) Presentations Bayesian Group-Sequential Design for COVID19 Vaccine Development Satrajit Roychoudhury (Pfizer) Bayesian Thinking A Personal View Motivated by COVID Stephen Ruberg (Analytix Thinking) Panel Discussion: Bayesian Methods in COVID Research and Innovative Clinical Trials Panel: Brian Hobbs (UT Austin); Satrajit Roychoudhury (Pfizer); Stephen Ruberg (Analytix Thinking); Ben Saville (Berry Consultants) Moderators: Jennifer Clark (FDA); Haijun Ma (Exelixis); Melissa Spann (Eli Lilly) Wrap-up
DIA Bayesian Scientific Working Group (BSWG) Members Group of representatives from Regulatory, Academia, and Industry, engaging in scientific discussion and collaboration Vision Ensure that Bayesian methods are well-understood, accepted, and broadly utilized for design, analysis, and interpretation to improve patient outcomes throughout the medical product development process and to improve decision making.
DIA BSWG Lead Team Subteam leaders: Chair: Freda Cooner (Arcutis) Vice-Chair: Pritibha Singh (Novartis) Advisors: Karen Price (Eli Lilly), Amy Xia (Amgen), Fanni Natanegara (Eli Lilly) Secretary: Melissa Spann (Eli Lilly) Publication Chair: Samiran Ghosh (Univ of Texas) Webmasters: Haijun Ma (Exelixis); Melvin Munsaka (Abbvie) Amy LaLonde (Eli Lilly), Bin Yao (Puma Biotechnology), Bob Campbell (Brown), Carl DiCasoli (Halozyme), Cory Heilmann (Eli Lilly), Deborah Wenkert (Wenkert & Young, LLC and Shriner s Hospital for Children), Jennifer Clark (FDA), Jiajun Liu (Biogen), Joan Buenconsejo (BMS), John Zhong (Regenxbio), Mani Lakshminarayanan (Statistical consultant), Margaret Gamalo (Pfizer), Larry Gould (Merck), Melvin Munsaka (Abbvie), Paul Faya (Eli Lilly), Percy Sondag (Merck), Ross Bray (Eli Lilly), Satrajit Roychoudhury (Pfizer), Tom Bradstreet (BMS), Xiang Zhang (CSL Behring), Yushi Liu (Eli Lilly), Zoran Antonijevic (Medsource)
Activities Monthly Key Opinion Leader (KOL) Webinar Series (third Friday) CID mini-series ongoing Slides: http://www.bayesianscientific.org/kol-lecture-series/ YouTube Channel: https://www.youtube.com/channel/UCS87g6cDalVzoCnsVS5E3Cg All-member working group meeting (2-3 times a year) Newsletter (semi-annually) Collaborations with DIA IDSWG, DIA stats and data science community, ASA Biopharmaceutical Section Update website to include more information (volunteer needed)
DIA BSWG Subteams In collaboration with IDSWG Pediatrics & Small Population Joint modeling Missing Data Master Protocol Safety Education Medicine Adaptive Pathways to Medicines Program wide Decision Making Historical Data/ Prior Spec Benefit- Risk Reporting & Tools Best Practices AD COVID- 19 Non- inferiority Non- Clinical RWE DCT Medical Outreach Survey
